News | January 27, 2009

Cardiogenesis' STS Symposium Explored Stem Cell Applications in Cardiovascular Medicine

January 28, 2009 - Attended by over 40 cardiothoracic surgeons, Cardiogenesis Corp.'s education symposium at the recent Society of Thoracic Surgeons Meeting in San Francisco was entitled "Advancements in Revascularization & Stem Cell Therapy."

Program Chair Emerson Perin, M.D., director, New Interventional Cardiovascular Technology, Texas Heart Institute said, "The objective of the symposium is to provide cardiac surgeons with a state-of-the-art update on the application of stem cells in cardiovascular medicine, including exciting new information on TMR [transmyocardial revascularization] plus cell therapy. Cardiologists are challenged everyday in treating medically refractory patients suffering from chronic ischemia.

"This program highlights recent advancements with TMR plus cell therapy for the treatment of chronic ischemia, including innovative new tools available to surgeons today. While there is still much to be learned about the therapeutic potential of stem cells, the safety and feasibility of autologous bone marrow stem cells in cardiac applications is well established. There are obvious advantages to intramyocardial cell delivery in the surgical setting - including precision and control, and the strategy of delivering platelet rich plasma in conjunction with minimally invasive TMR is a logical initial step."

The symposium included presentations of real world experiences with TMR as well as TMR plus cell therapy, including:

- Guillermo Reyes, M.D., a cardiothoracic surgeon from Madrid presented his early experience using the Cardiogenesis PHOENIX delivery system, which in this series combined TMR plus autologous bone marrow stem cells. The 12- month outcomes on 16 patients included the elimination or significant reductions in angina, with no mortality and no major adverse events.
- Kurt Wehberg, M.D., a cardiothoracic surgeon from Salisbury, MD described the implementation of a minimally invasive Fast Track TMR program. Using a strict patient care protocol, combined with minimally invasive thoracotomy technique, he reported a time to discharge postoperatively of 23 hours for 80 percent of his stand-alone TMR patients. Dr. Wehberg also presented six-month follow up on 11 patients treated with TMR plus platelet rich plasma (PRP). The six-month outcomes included a significant reduction in angina (82 percent of patients free of angina) and a trend toward improvement in ejection fraction.

For more information: www.cardiogenesis.com

Related Content

Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery | May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Overlay Init